Video Shorts

The Biggest Challenge for Emerging Biotechs

The 90% Problem: Why Most Biotech Assets Fail

Why Women Were Excluded from Clinical Trials

The Return of Biotech: M&A Activity, Investment, and Industry Growth

The 'Non-Magic' Secret to Faster Biotech Timelines

Why Human Data is Replacing Animal Studies in Antibody Development

How 10 People Reached Clinical-Stage Drug Discovery Using AI

Why Flexibility is the Secret to Modern Biotech Deals

The Future of Cancer Treatment: Moving Beyond Traditional ADCs

What Actually Matters in Drug Development

Should We Replace Animal Testing in Cancer Research?

Why Great Biotech Ideas Fail to Scale

Scaling Your Biotech Assets: Key Success Factors

Targeting Multi-Pathway Disease in Babies

The Million Dollar Question: Who Wins the Next Decade of Biomanufacturing?

What Still Excites You About Coming to a Conference Like BIO?

The Conversation You Wish to Have with Every Founder Before Signing Their First CDMO

The 'Optimism' Trend at This Year's BIO

One Clause Every Biotech CEO Should Beware in Deals Right Now

Why Nature Outperforms AI in Drug Discovery

Which Would You Choose, Complement Activation or Neutrophil Activity?

One Thing You Discovered in Human Antibody Data That Surprised You

Making Cancer a Chronic Disease: The Shift to Kinder Treatments

The Major Shift from Chemotherapy to Targeted Therapy

Building a Billion-Dollar Dream Team

Hope Behind Positive Kimmtrak Data

3D Printing Bones: The Future of Biomedical Engineering

The Secret to a Thriving Biotech Ecosystem

Don't Compromise Biology for Manufacturing Scalability

Why Great Science Fails without Scale